CVS Advanced PLUS Blood Glucose Monitoring System
I-Sens, Inc. · Decision date Oct 2, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision on 2026-10-02 for K260689, the CVS Advanced PLUS Blood Glucose Monitoring System, submitted by I-Sens, Inc. of Seoul, KR. The device falls under product code NBW, the over-the-counter blood glucose test system classification, regulation 862.1345, with the review assigned to the Clinical Chemistry panel. The record shows the application was received 03/03/2026 and was not reviewed by a third party.
SESE in a 510(k) means the device was cleared as substantially equivalent to a legally marketed predicate; it is not a PMA approval. The public record does not identify the predicate device, the specific components or changed items described in the submission, or any performance data supporting the decision. The Decision Summary PDF is linked but its contents are not included here, so the basis for equivalence remains unverified from this source.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Clinical Chemistry
- Decision date
- Oct 2, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K260689
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- I-Sens, Inc.
- Product code
- NBW
- Decision code
- SESE
- Decision date
- Oct 2, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: System, Test, Blood Glucose, Over The Counter.
- Applicant
- I-Sens, Inc.
- Product code
- NBW
- FDA device class
- 2
FDA decision timeline
K260689 received
Application receipt date recorded by FDA.
K260689 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code NBW
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Changsha Sinocare, Inc. | 510(k) clearance | Oct 30, 2026 | FDA | |
| EPS Bio Technology Corp. | 510(k) clearance | Oct 23, 2026 | FDA | |
| Vivachek Biotech (Hangzhou) Co., Ltd. | 510(k) clearance | Oct 9, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
I-Sens, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Seoul
Sources and methodology
- Original FDA record: K260689
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

